Dr. Alexandra Goll joined TVM Capital in early 1998, and has since been responsible for more than 20 TVM Capital life science investments. She was an initial investor in Actelion Ltd (Allschwil, Switzerland) and a Series B lead investor of Idenix Pharmaceuticals, Inc. (Cambridge, Massachusetts). Dr. Goll was a member of the Board of Directors of Idenix until the sale of 51% of the company to Novartis in May 2003.
Currently, Dr. Goll serves on the Board of Directors of Albireo (Gothenburg, Sweden), Biovertis AG (Vienna, Austria), Cerenis Therapeutics (Toulouse, France and Ann Arbor, MI) and Wilex AG (Munich, Germany). She also represents the interests of TVM Capital with Addex Pharmaceuticals SA (Geneva, Switzerland), Ark Therapeutics Ltd. (London, UK), EUSA Pharma Ltd. (Europe), GPC Biotech AG (Martinsried, Germany), MediGene AG (Martinsried) and Newron Pharmaceuticals SpA, (Bresso, Italy).
Prior to her affiliation with TVM Capital, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Roche Ltd. in Basel. She had been involved in clinical development and managing commercialization strategies of products such as Neupogen® (under an agreement with Amgen), Hivid®, Cymevene® and Valcyte®. Dr. Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was also honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine.
